Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Carcinoma, Medullary × fluorodopa F 18 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Glioma 9 Glioblastoma 5 Neuroendocrine Tumors 3 Hypoglycemia 3 Congenital Hyperinsulinism 3 Recurrence 2 Parkinson Disease 2 Neuroblastoma 2 Insulinoma 2 Hyperinsulinism 2 Brain Neoplasms 2 Parathyroid Neoplasms 1 Oligodendroglioma 1 Multiple Endocrine Neoplasia 1 Lewy Body Disease 1 Infant, Newborn, Diseases 1 Hyperparathyroidism 1 Hypercalcemia 1 Glucose Metabolism Disorders 1 Gliosarcoma 1 Glioma, Subependymal 1 Ependymoma 1 Carcinoma, Medullary 1 Astrocytoma 1

Interventions

vandetanib 12 cabozantinib 7 selpercatinib 5 Everolimus 5 Sorafenib 4 Magnetic Resonance Spectroscopy 3 Capecitabine 3 sargramostim 2 pralsetinib 2 lutetium Lu 177 dotatate 2 lenvatinib 2 Trastuzumab 2 Temozolomide 2 Sunitinib 2 Octreotide 2 Gefitinib 2 yeast-CEA vaccine 1 veliparib 1 vatalanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 temsirolimus 1 tanespimycin 1 sacubitril and valsartan sodium hydrate drug combination 1 ponatinib 1 pentetreotide 1 pembrolizumab 1 pazopanib 1 pasireotide 1 nintedanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02856347 2025-11-18

CMTpostopFDOPA

Institut Claudius Regaud

Phase NA Completed

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡